Jenburkt Pharma Reports ₹34.74 Cr Profit for FY26, Recommends ₹20.70 Dividend

Jenburkt Pharmaceuticals Ltd reported its financial results for the fiscal year ending March 31, 2026. The company posted revenue from operations of ₹168.74 crore and a Profit After Tax (PAT) of ₹34.74 crore.

Key Financials and Appointments

Jenburkt Pharmaceuticals announced its standalone audited financial results for the fiscal year ended March 31, 2026. The company reported a Profit After Tax (PAT) of ₹3,473.60 lakh (₹34.74 crore), with Earnings Per Share (EPS) at ₹78.71. Revenue from operations reached ₹16,874.06 lakh (₹168.74 crore). The board has proposed a dividend of ₹20.70 per equity share for FY 2025-26.

In governance updates, Shri Dilip H. Bhuta was appointed as a director and re-appointed as Whole Time Director & CFO. His re-appointment as WTD & CFO is set for a five-year term commencing April 1, 2027.

The company also scheduled its 41st Annual General Meeting (AGM) for September 4, 2026, where shareholder approval for these appointments will be sought.

Management and Shareholder Impact

The recommended dividend of ₹20.70 per share, subject to shareholder approval at the AGM, offers a direct return to investors and reflects the company's profitability. The re-appointment of Shri Dilip H. Bhuta as Whole Time Director & CFO ensures continuity in financial leadership and strategic direction. These governance changes aim to strengthen financial oversight and execution.

Company Background

Jenburkt Pharmaceuticals is an Indian company manufacturing and marketing a range of pharmaceutical formulations for domestic and international markets across various therapeutic areas.

Potential Risks

No specific risks or negative events were highlighted in the company's filing or identified in preliminary checks.

Industry Context

Jenburkt Pharmaceuticals operates in the competitive Indian pharmaceutical sector. Peers such as Eris Lifesciences and Alembic Pharmaceuticals face similar market dynamics and regulatory environments with their focus on branded generics and diverse portfolios, respectively. Specific financial comparisons for this reporting period against these peers are not available from the filing.

Key Financial Metrics

Revenue from operations for FY 2025-26 was ₹16,874.06 lakh (₹168.74 crore) on a standalone basis. Profit After Tax for the same period was ₹3,473.60 lakh (₹34.74 crore). Earnings Per Share (EPS) stood at ₹78.71.

Looking Ahead

Investors will track shareholder approval for Shri Dilip H. Bhuta's appointments at the AGM on September 4, 2026. The company's performance in upcoming quarters, focusing on revenue growth and margin trends, will also be key. Future announcements on product launches or market expansion, along with management commentary on the company's outlook, will be important to monitor.